Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.37 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 6/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27950252 | 0.92 | PPARG (0.38) | PPARGPPARAPPARDMRGPRX4RORC | |
| SCHEMBL27936024 | 0.91 | PPARG (0.39) | PPARGPPARAPPARDRORCNLRP3 | |
| SCHEMBL27936025 | 0.89 | PPARG (0.36) | PPARGPPARAPPARDRORCNLRP3 | |
| Piperazine SCHEMBL27950239 | 0.87 | PPARG (0.36) | PPARGPPARAPPARDRORCNLRP3 | |
| SCHEMBL27936030 | 0.86 | PPARG (0.37) | PPARGPPARAPPARDRORCACLY | |
| SCHEMBL27950242 | 0.86 | PPARG (0.38) | PPARGPPARAPPARDRORC | |
| SCHEMBL27950301 | 0.86 | PPARG (0.37) | PPARGPPARAPPARDMRGPRX4RORC | |
| SCHEMBL28809330 | 0.85 | PPARG (0.37) | PPARGPPARAPPARDRORC | |
| SCHEMBL27936038 | 0.85 | PPARG (0.38) | PPARGPPARAPPARD | |
| SCHEMBL28810371 | 0.84 | MEN1 (0.36) | PPARGRORCNLRP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103554006-A | Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease | FOURNIER LAB SA | 2014-02-05 | — | — | CN | disclosed |